BioPharma Dive June 6, 2024
The deal, worth up to $50 million, adds to a pipeline GSK is building around nucleic acid drugs, including its hepatitis B candidate bepirovirsen.
British drugmaker GSK is investing further in nucleic acid drug development, reaching a deal to buy the San Diego-based Elsie Biotechnologies for as much as $50 million.
GSK announced the deal Thursday, almost one year after beginning a research collaboration around oligonucleotides with the private biotechnology company. Buying Elsie will give GSK full access to the company’s discovery and delivery technologies, fitting into GSK’s broader commitment to explore oligonucleotide drugs.
The acquisition comes about four months after GSK exercised an option to license Elsie’s platform for an undisclosed upfront payment.
Oligonucleotides are small strands of DNA...
Today's Sponsors
Today's Sponsor